Celltrion unveils promising dose escalation results for subcutaneous infliximab

Study reveals potential new strategy for managing inflammatory bowel disease

Celltrion has announced groundbreaking results from a two-year study on dose escalation of subcutaneous infliximab (CT-P13 SC) therapy.

This news was presented at United European Gastroenterology (UEG) Week 2024 in Vienna, highlighting a potential new approach for managing inflammatory bowel disease (IBD).

A post-hoc analysis of the LIBERTY-CD (Crohn’s disease) and LIBERTY-UC (ulcerative colitis) studies showed that patients initially responding to intravenous (IV) induction but losing response subsequently, experienced significant improvement with dose escalation of CT-P13 SC.

Over 102 weeks, clinical remission rates improved markedly, with 70.3% of Crohn’s disease patients and 35.2% of ulcerative colitis patients showing remission. Endoscopic responses were seen in 40.5% of Crohn’s disease patients.

Prof Stefan Schreiber from University Hospital Schleswig-Holstein in Kiel commented, “Dose escalation has long been an option for individual optimisation of IBD patients, particularly in those who lose response after induction therapy with IV infliximab. The post-hoc analysis indicates that dose escalation of CT-P13 SC is a possibility to restore efficacy and optimise outcomes in those who initially responded to induction.”

The study reported no new safety concerns, making dose escalation a viable strategy for long-term management of moderately to severely active IBD.

Kevin Byoung Seo Choi, Executive VP at Celltrion, stated, “The updated SmPC in Crohn’s disease notes that patients who initially responded to 5mg/kg but lost response may regain response with dose escalation. These findings provide healthcare professionals with a personalised approach to IBD care.”

Celltrion’s partnership with UEGW underscores its commitment to advancing IBD treatment options, aiming to improve patient outcomes through innovative therapeutic strategies.